Regenex NK Cells — Natural Killer Cell Product
Expanded and activated natural killer cells manufactured for use in supportive cancer immunotherapy and viral immune reconstitution. Every batch is functionally tested with a cytotoxicity assay — confirming the cells can kill target cells, not just that they're alive.
Full Product Specifications
| Cell Type | Natural Killer Cells |
| Phenotype | CD56+ CD3− (verified by flow cytometry) |
| Source | Allogeneic — screened healthy donors |
| Activation Method | Cytokine stimulation (IFN-γ, IL-2, anti-CD3) |
| Expansion Period | 14–21 days |
| Viability (release) | ≥90% live cells at release |
| Sterility | No bacterial or fungal growth at 14 days |
| Endotoxin | <0.5 EU/mL |
| Mycoplasma | Negative (PCR-based testing) |
| Cytotoxicity Assay | Functional killing assay — result on CoA |
| Activating Receptors | NKG2D, NKp46, NKp30 — verified by flow cytometry |
| Storage | Fresh (preferred) or cryopreserved |
| Packaging | Infusion bag — single-use |
| Traceability | Blockchain-verified |
| Documentation | Certificate of Analysis per batch |
Clinical Applications
Regenex NK cell products are used in supportive cancer immunotherapy for blood and solid cancers, HIV immune reconstitution, hepatitis B immune support and general immune strengthening. All applications are conducted under physician supervision.
View NK Cell Therapy clinical informationCytotoxicity Testing — Why It Matters
Many NK cell manufacturers report cell count and viability — but not functional potency. A batch of NK cells with high viability but low cytotoxic activity is therapeutically useless. Regenex tests every batch with a functional cytotoxicity assay against a validated target cell line. The kill ratio is documented on the Certificate of Analysis.
Enquire About NK Cell Supply
Regenex NK cell products are available for clinical supply to oncology clinics, hospitals and immunology centres.